CN115368473A - 一种特异性识别baff-r的嵌合抗原受体分子及其应用 - Google Patents

一种特异性识别baff-r的嵌合抗原受体分子及其应用 Download PDF

Info

Publication number
CN115368473A
CN115368473A CN202210546011.4A CN202210546011A CN115368473A CN 115368473 A CN115368473 A CN 115368473A CN 202210546011 A CN202210546011 A CN 202210546011A CN 115368473 A CN115368473 A CN 115368473A
Authority
CN
China
Prior art keywords
baff
amino acid
seq
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210546011.4A
Other languages
English (en)
Chinese (zh)
Inventor
张新敏
粘伟红
许传营
何峰
周清
张剑冰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Yinuolai Biotechnology Co ltd
Shanghai Shijian Biotechnology Co ltd
Original Assignee
Guangzhou Yinuolai Biotechnology Co ltd
Shanghai Shijian Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Yinuolai Biotechnology Co ltd, Shanghai Shijian Biotechnology Co ltd filed Critical Guangzhou Yinuolai Biotechnology Co ltd
Publication of CN115368473A publication Critical patent/CN115368473A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202210546011.4A 2021-05-19 2022-05-19 一种特异性识别baff-r的嵌合抗原受体分子及其应用 Pending CN115368473A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/094605 2021-05-19
CN2021094605 2021-05-19

Publications (1)

Publication Number Publication Date
CN115368473A true CN115368473A (zh) 2022-11-22

Family

ID=84060535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210546011.4A Pending CN115368473A (zh) 2021-05-19 2022-05-19 一种特异性识别baff-r的嵌合抗原受体分子及其应用

Country Status (6)

Country Link
US (1) US20250268939A1 (enExample)
EP (1) EP4342913B1 (enExample)
JP (1) JP7901840B2 (enExample)
CN (1) CN115368473A (enExample)
TW (1) TW202300520A (enExample)
WO (1) WO2022242710A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067496A1 (zh) * 2023-09-28 2025-04-03 南京驯鹿生物技术股份有限公司 靶向baff-r的全人源抗体、car-t细胞及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241730B (zh) * 2024-12-09 2025-03-04 天津医科大学总医院空港医院 一种分泌il10靶向baffr嵌合抗原受体、car-t细胞和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CN101851291B (zh) * 2010-02-09 2011-10-26 中国人民解放军第四军医大学 一种抗人baff单克隆抗体的重链和轻链可变区
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP3464371B1 (en) * 2016-06-06 2026-07-29 City of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
SG11202008008UA (en) * 2018-02-21 2020-09-29 Univ Texas Universal antigen presenting cells and uses thereof
WO2021163989A1 (en) 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067496A1 (zh) * 2023-09-28 2025-04-03 南京驯鹿生物技术股份有限公司 靶向baff-r的全人源抗体、car-t细胞及其应用

Also Published As

Publication number Publication date
EP4342913A1 (en) 2024-03-27
EP4342913B1 (en) 2025-12-17
TW202300520A (zh) 2023-01-01
EP4342913A4 (en) 2024-11-20
EP4342913C0 (en) 2025-12-17
WO2022242710A1 (zh) 2022-11-24
JP7901840B2 (ja) 2026-08-07
US20250268939A1 (en) 2025-08-28
JP2024519943A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
US20230355673A1 (en) Chimeric antigen receptors targeting tim-1
CN108715859B (zh) 靶向cd22的嵌合抗原受体及其应用
CA3173394A1 (en) Methods of making chimeric antigen receptor-expressing cells
CN113412117A (zh) 嵌合抗原和t细胞受体及使用的方法
CN113248616B (zh) 靶向gpc3的嵌合抗原受体及其用途
WO2018121712A1 (zh) 一种新型嵌合抗原受体及其应用
CN115003698A (zh) 抗tcr抗体分子及其用途
WO2021233317A1 (en) Il-12 armored immune cell therapy and uses thereof
US20210069246A1 (en) Combination therapy using adoptive cell therapy and checkpoint inhibitor
US20230192848A1 (en) Engineered cell compositions and methods of use thereof
WO2023173272A1 (zh) 靶向gprc5d的全人源嵌合抗原受体(car)及其应用
US20250297029A1 (en) Anti-gpc3 chimeric antigen receptor and methods of use thereof
WO2023088359A1 (zh) 靶向bcma的嵌合抗原受体及其应用
WO2023016576A1 (zh) 基于全人源及鼠源单链抗体的靶向bcma的嵌合抗原受体及其用途
US20250268939A1 (en) Chimeric Antigen Receptor Molecule for Specifically Recognizing Baff-R and Application of Chimeric Antigen Receptor Molecule
WO2023217062A1 (zh) 一种嵌合抗原受体及其应用
WO2025148750A1 (zh) 膜表达il-10及其用途
US20250179170A1 (en) Use of anti-claudin-1 antibodies to increase t cell availability
WO2024140641A1 (zh) 靶向ror1的抗原结合蛋白
WO2023274386A1 (zh) 靶向egfr的通用型car-t细胞及其制备方法
CN119912567B (zh) 一种表达靶向B7-H3的嵌合抗原受体的Vγ9Vδ2 T细胞及其应用
WO2026061386A1 (zh) Gpc3 car及其应用
HK40104616A (en) Anti-gpc3 chimeric antigen receptor and methods of use thereof
CN118271440A (zh) 靶向IL13Rα2的抗体以及靶向IL13Rα2的免疫效应细胞
HK40101165A (en) Engineered immune cells and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination